Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations

Clinical Genetics

Volumn 83, Issue 3, 2013, Pages 232-237

  Narod, S A ^a   Moody, J R K ^b   Rosen, B ^a   Fan, I ^b   Risch, A ^c   Sun, P ^a   Mclaughlin, J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Ovarian cancer; Survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CANADA; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RURAL AREA;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; FEMALE; GENETIC TESTING; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; ONTARIO; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84874017751     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01906.x     Document Type: Article

References (11)

1. Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011: 121: 353-357.
2. Antoniou AC, Pharoah PD, Narod S et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005: 42: 602-603.
3. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000: 283: 2260-2265.
4. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003: 97: 2187-2195.
5. Tan DS, Rothermundt C, Thomas K et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008: 26: 5530-5536.
6. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008: 26: 20-25.
7. Yang D, Khan S, Sun Y et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011: 306: 1557-1565.
8. Hyman DM, Zhou Q, Iasonos A et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2011. Epub 2 December 2011.
9. Bolton KL, Chenevix-Trench G, Goh C et al. Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012: 307 (4): 382-390.
10. Rennert G, Bisland-Naggan S, Barnett-Griness O et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007: 357 (2): 115-123.
11. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000: 283 (17): 2260-2265.